Alakananda Basu

Prof. Alakananda Basu

Department of Microbiology, Immunology & Genetics, University of North Texas Health Science Center, Fort Worth, TX, USA
orcid

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Journal of Nucleic Acids
Verified
Journal Article
Open access
PDF file
Alakananda BasuAlakananda Basu
Alakananda Basu
SKSoumya Krishnamurthy
Soumya Krishnamurthy
Cisplatin is one of the most effective anticancer agents widely used in the treatment of solid tumors. It is generally considered as a cytotoxic drug which kills cancer cells by damaging DNA and inhibiting DNA synthesis. How cells respond to cisplatin‐induced DNA damage plays a critical role in deciding cisplatin sensitivity. Cisplatin‐induced DNA damage activates various signaling pathways to prevent or promote cell death. This paper summarizes our current understandings regarding the mechanisms by which cisplatin induces cell death and the bases of cisplatin resistance. We have discussed various steps, including the entry of cisplatin inside cells, DNA repair, drug detoxification, DNA damage response, and regulation of cisplatin‐induced apoptosis by protein kinases. An understanding of how various signaling pathways regulate cisplatin‐induced cell death should aid in the development of more effective therapeutic strategies for the treatment of cancer.

30 September 1988 in Science
Verified
Journal Article
Closed access
PDF file
SKSusan L. Kelley
Susan L. Kelley
Alakananda BasuAlakananda Basu
Alakananda Basu
BTBeverly A. Teicher
Beverly A. Teicher
MHMiles P. Hacker
Miles P. Hacker
DHDean H. Hamer
Dean H. Hamer
JLJohn S Lazo
John S Lazo
Resistance to antineoplastic agents is the major obstacle to curative therapy of cancer. Tumor cell lines with acquired resistance to the antineoplastic agent cis -diamminedichloroplatinum(II) overexpressed metallothionein and demonstrated cross-resistance to alkylating agents such as chlorambucil and melphalan. Human carcinoma cells that maintained high levels of metallothionein because of chronic exposure to heavy metals were resistant to cis -diamminedichloroplatinum(II), melphalan, and chlorambucil. Furthermore, cells transfected with bovine papilloma virus expression vectors containing DNA encoding human metallothionein-II A were resistant to cis -diamminedichloroplatinum(II), melphalan, and chlorambucil but not to 5-fluorouracil or vincristine. Thus, overexpression of metallothionein represents one mechanism of resistance to a subset of clinically important anticancer drugs.

24 September 2019 in Cancers
Verified
Journal Article
Open access
PDF file
ADAkpedje Serena Dossou
Akpedje Serena Dossou
Alakananda BasuAlakananda Basu
Alakananda Basu
Autophagy is a process of self-degradation that enables the cell to survive when faced with starvation or stressful conditions. The mechanistic target of rapamycin (mTOR), also known as the mammalian target of rapamycin, plays a critical role in maintaining a balance between cellular anabolism and catabolism. mTOR complex 1 (mTORC1) was unveiled as a master regulator of autophagy since inhibition of mTORC1 was required to initiate the autophagy process. Evidence has emerged in recent years to indicate that mTORC1 also directly regulates the subsequent steps of the autophagy process, including the nucleation, autophagosome elongation, autophagosome maturation and termination. By phosphorylating select protein targets of the autophagy core machinery and/or their regulators, mTORC1 can alter their functions, increase their proteasomal degradation or modulate their acetylation status, which is a key switch of the autophagy process. Moreover, it phosphorylates and alters the subcellular localization of transcription factors to suppress the expression of genes needed for autophagosome formation and lysosome biogenesis. The purpose of this review article is to critically analyze current literatures to provide an integrated view of how mTORC1 regulates various steps of the autophagy process.

9 June 2011 in Cancers
Verified
Journal Article
Open access
PDF file
SSSavitha Sridharan
Savitha Sridharan
KJKirti Jain
Kirti Jain
Alakananda BasuAlakananda Basu
Alakananda Basu
Autophagy is a process of self-degradation that maintains cellular viability during periods of metabolic stress. Although autophagy is considered a survival mechanism when faced with cellular stress, extensive autophagy can also lead to cell death. Aberrations in autophagy are associated with several diseases, including cancer. Therapeutic exploitation of this process requires a clear understanding of its regulation. Although the core molecular components involved in the execution of autophagy are well studied there is limited information on how cellular signaling pathways, particularly kinases, regulate this complex process. Protein kinases are integral to the autophagy process. Atg1, the first autophagy-related protein identified, is a serine/threonine kinase and it is regulated by another serine/threonine kinase mTOR. Emerging studies suggest the participation of many different kinases in regulating various components/steps of this catabolic process. This review focuses on the regulation of autophagy by several kinases with particular emphasis on serine/threonine protein kinases such as mTOR, AMP-activated kinase, Akt, mitogen-activated protein kinase (ERK, p38 and JNK) and protein kinase C that are often deregulated in cancer and are important therapeutic targets.

1 January 1993 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
Alakananda BasuAlakananda Basu
Alakananda Basu